Business Context and Reporting Period
This Form 8-K Current Report from iSpecimen Inc. (ISPC) covers the event date of December 1, 2021. The filing announces the closing of a private placement offering of common stock and warrants. The Company is an emerging growth company incorporated in Delaware, with its principal executive offices in Lexington, MA.
Key Financial Metrics and Transaction Details
- Gross Proceeds: Approximately $21,000,000.
- Securities Issued: 1,749,999 shares of Common Stock and warrants exercisable for 1,312,500 shares.
- Warrant Terms: 5.5-year term; exercise price of $13.00 per share; immediately exercisable on a cashless basis after six months or upon registration effectiveness.
- Transaction Costs: Placement agent fee of 6.0% of the aggregate purchase price plus expenses up to $75,000.
- Use of Proceeds: Working capital purposes.
- Other Metrics: The filing does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity ratios.
Material Changes
The primary material change is the increase in equity capital and potential future share count due to the issuance of 1,749,999 new shares and warrants for an additional 1,312,500 shares. This transaction was executed pursuant to a securities purchase agreement dated November 28, 2021, with accredited investors under Section 4(a)(2) and/or Regulation D exemptions.
Outlook, Risks, and Management Commentary
Management intends to use the net proceeds for working capital. The filing includes standard forward-looking statement disclaimers, noting that actual results may differ materially due to risks and uncertainties. The Company plans to file one or more registration statements to register the resale of the Shares and Warrant Shares.
Investor Verification Checklist
- Verify the exact net proceeds after deducting the 6.0% placement fee and the $75,000 expense cap.
- Confirm the dilution impact of the 1,749,999 issued shares and the potential 1,312,500 warrant shares on existing shareholders.
- Monitor the filing of the registration statement for the resale of the securities to ensure liquidity for investors.
- Review the Company's subsequent financial reports to assess the utilization of the $21 million in working capital.